Page 1

West Ⓡ ● By your side for a healthier world ™ ● West Announces First - Quarter 2021 Results · Conference Call Scheduled for 9 a.m. EDT Today - Exton , PA , April 29 , 2021 - West Pharmaceutical Services , Inc. ( NYSE : WST ) today announced its financial results for the first - quarter 2021 and updated full - year 2021 financial guidance . First - Quarter 2021 Summary ( comparisons to prior - year period ) Net sales of $ 670.7 million grew 36.5 % ; organic sales growth was 31.1 % . Reported - diluted EPS of $ 1.99 increased 101 % . Adjusted - diluted EPS of $ 2.05 increased 103 % . Exhibit 99.1 The Company is raising full - year 2021 net sales guidance to a new range of $ 2.630 billion to $ 2.655 billion , compared to a prior range of $ 2.500 billion to $ 2.525 billion . The Company is raising full - year 2021 adjusted - diluted EPS guidance to a new range of $ 6.95 to $ 7.10 , compared to a prior range of $ 6.00 to $ 6.15 . " Adjusted - diluted EPS " and " organic sales growth " are Non - U.S . GAAP measurements . See discussion under the heading " Non - U.S . GAAP Financial Measures " in this release . " We delivered another solid performance in the first quarter with strong organic sales growth from both our base business as well as increased demand for our products associated with COVID - 19 vaccines , " said Eric M. Green , President and Chief Executive Officer . " I am proud of the relentless focus and consistent execution of our global team members to deliver critical components and solutions during these times . With a strong start to the year , we are raising our full - year financial guidance . West will continue to play an integral role with our customers as they develop and bring new medicines to the market for a brighter future . " Proprietary Products Segment Net sales grew by 45.6 % to $ 543.7 million . Organic sales growth was 39.6 % with currency translation increasing sales growth by 600 basis points . High - value products ( components and devices ) represented more than 70 % of segment sales and generated double - digit organic sales growth , led by customer demand for FluroTec® , Westar® , DaikyoⓇ and NovaPure® components as well as for devices such as Daikyo Crystal Zenith® syringes and cartridges . All three market units had double - digit organic sales growth , led by strong performance in the Biologics market unit .